Roche has agreed not to oppose Amgen's request for a limited exclusion order that would block the import of Roche's anemia drug Mircera into the U.S.rnAmgen filed a motion recently with the U.S. International Trade Commission (ITC) asking for a summary determination that Roche had violated a section of the Smoot-Hawley Tariff Act by importing the pegylated erythropoietin (EPO) product Mircera (methoxy polyethylene glycol-epoetin beta).rnThe dispute centers on Amgen's patents on two other erythropoeisis-stimulating agents -Epogen (epoetin alfa) and Aranesp (darbepoetin alfa). Amgen initially filed its complaint with the ITC in April 2006 "seeking prompt adjudication of its claim to exclude Roche's importation of its infringing pegylated EPO product," according to ITC documents.
展开▼
